Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 28, 2006CancerOpen Access

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEmilio BriaUniversità Cattolica del Sacro CuoreCNCecilia NisticòUniversity of VeronaFCFederica CupponeItalian Medicines Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bria et al. (2006) studied this question.

synapsesocial.com/papers/6a9dfd4a4c53cd4efa42beedhttps://doi.org/10.1002/cncr.21886
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)2005 · 66 citations
  2. 2Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results2002 · 1,089 citations
  3. 3Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer2003 · 79 citations
  4. 4Survival Analysis: A Practical Approach.1996 · 737 citations
  5. 5Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.1998 · 548 citations